Pharvaris N.V. (PHVS) 10-Year Financial Performance & Capital Metrics

PHVS • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.Show more

Revenue $0
EBITDA -$146M -50.6%
Net Income -$134M -33.1%
EPS (Diluted) -2.48 +5.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -41.18% -8.9%
ROIC -
Debt/Equity 0.00 +417.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 40.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-23.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM-19.18%

ROCE

10Y Avg-54.1%

5Y Avg-43.14%

3Y Avg-43.3%

Latest-44.66%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	0	614	8.44K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	0	-614	-8.44K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-12.73%	1%	-	-	-
Operating Expenses+	4.31M	8.96M	28.5M	54.14M	86.71M	96.91M	145.69M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	668.12K	2.6M	6.26M	18.35M	29.34M	31.34M	47.12M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	3.65M	6.36M	22.24M	35.79M	57.38M	65.58M	98.56M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-4.31M	-8.97M	-28.51M	-54.14M	-86.71M	-96.91M	-145.69M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-1.08%	-2.18%	-0.9%	-0.6%	-0.12%	-0.5%
EBITDA+	0	-8.96M	-28.5M	-54.06M	-86.56M	-96.66M	-145.59M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-2.18%	-0.9%	-0.6%	-0.12%	-0.51%
D&A (Non-Cash Add-back)	4.31M	614	8.44K	77.37K	152.94K	257.55K	95K
EBIT	-4.31M	-8.98M	-29.72M	-54.14M	-86.71M	-96.91M	-145.69M
Net Interest Income+	0	4	-92.38K	-277.91K	-16.09K	0	5.47M
Interest Income	0	4	92	268	16	0	5.47M
Interest Expense	0	0	92.47K	278.18K	16.11K	0	0
Other Income/Expense	-380	-18.89K	-1.21M	11.48M	11.06M	-2.91M	13.29M
Pretax Income+	-4.31M	-8.98M	-29.72M	-42.66M	-75.65M	-99.83M	-132.4M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	380	0	-94.9K	70.12K	679.09K	1.05M	1.83M
Effective Tax Rate %	1%	1%	1%	1%	1.01%	1.01%	1.01%
Net Income+	-4.31M	-8.98M	-29.62M	-42.73M	-76.33M	-100.88M	-134.22M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-1.08%	-2.3%	-0.44%	-0.79%	-0.32%	-0.33%
Net Income (Continuing)	-4.31M	-8.98M	-29.62M	-42.73M	-76.33M	-100.88M	-134.22M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.14	-0.25	-0.85	-1.41	-2.27	-2.63	-2.48
EPS Growth %	-	-0.79%	-2.4%	-0.66%	-0.61%	-0.16%	0.06%
EPS (Basic)	-0.14	-0.25	-0.85	-1.41	-2.27	-2.63	-2.48
Diluted Shares Outstanding	31.84M	31.84M	30.52M	30.41M	33.59M	38.39M	54.02M
Basic Shares Outstanding	31.84M	31.84M	30.52M	30.41M	33.59M	38.39M	54.02M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.43M	20.58M	100.95M	211.57M	166.85M	397.85M	289.42M
Cash & Short-Term Investments	5.39M	20.33M	98.63M	209.35M	161.84M	391.23M	280.73M
Cash Only	5.39M	20.33M	98.63M	209.35M	161.84M	391.23M	280.73M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	0	210.84K	569.58K	700.08K	382.47K	1.04M	2.94M
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	4.04M	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	1.21M	5.7K	582.59K	620.82K	0
Total Non-Current Assets+	0	12.93K	147.84K	523.4K	886.24K	843.1K	1.96M
Property, Plant & Equipment	0	12.93K	48.5K	351.35K	626.44K	455.57K	1.48M
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0
Total Assets+	5.43M	20.6M	101.1M	212.09M	167.73M	398.69M	291.37M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	2.79%	3.91%	1.1%	-0.21%	1.38%	-0.27%
Total Current Liabilities+	481.34K	1.92M	5.31M	6.99M	18.22M	14.6M	22.97M
Accounts Payable	246.36K	517.77K	656.45K	2.13M	5.98M	2.91M	4.56M
Days Payables Outstanding	-	307.56K	28.4K	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	0	0	875.24K	1.46M	461.3K	429.92K	7.83M
Current Ratio	11.29x	10.70x	19.00x	30.28x	9.16x	27.25x	12.60x
Quick Ratio	11.29x	10.70x	19.00x	30.28x	8.93x	27.25x	12.60x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	246.36K	0	0	150.75K	249.42K	43.56K	639.04K
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	150.75K	249.42K	43.56K	639.04K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	-1	0	0	0
Total Liabilities	481.34K	1.92M	5.31M	7.14M	18.47M	14.65M	23.61M
Total Debt+	0	0	0	250.18K	436.82K	238.91K	861.47K
Net Debt	-5.39M	-20.33M	-98.63M	-209.1M	-161.4M	-390.99M	-279.87M
Debt / Equity	-	-	-	0.00x	0.00x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-308.28x	-194.62x	-5384.33x	-	-
Total Equity+	4.95M	18.67M	95.79M	204.95M	149.26M	384.05M	267.76M
Equity Growth %	-	2.77%	4.13%	1.14%	-0.27%	1.57%	-0.3%
Book Value per Share	0.16	0.59	3.14	6.74	4.44	10.00	4.96
Total Shareholders' Equity	4.95M	18.67M	95.79M	204.95M	149.26M	384.05M	267.76M
Common Stock	100.93K	130.96K	235.69K	3.98M	4.06M	6.27M	6.53M
Retained Earnings	-10.45M	-18.47M	-44.46M	-87.57M	-164.19M	-265.92M	-402.26M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	275.99K	392.14K	1.98M	9.8M	20.21M	27.88M	39.85M
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.92M	-6.68M	-21.5M	-44.6M	-67.16M	-93.05M	-120.13M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.7%	-2.22%	-1.07%	-0.51%	-0.39%	-0.29%
Net Income	-4.31M	-8.03M	-26.07M	-42.66M	-75.65M	-99.83M	-132.4M
Depreciation & Amortization	0	549	7.4K	77.37K	152.94K	257.55K	269.56K
Stock-Based Compensation	100.75K	116.15K	1.59M	8.2M	11.35M	10.66M	16.21M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	2.97K	-3.69K	1.4M	-11.79M	-11.39M	1.72M	-10.1M
Working Capital Changes	291.55K	1.24M	1.57M	1.58M	8.38M	-5.86M	5.89M
Change in Receivables	-49.52K	-208.73K	-358.74K	-130.5K	317.61K	-41.05K	-34.32K
Change in Inventory	0	3.58K	0	0	0	0	0
Change in Payables	188.45K	273.69K	0	0	0	0	0
Cash from Investing+	0	-13.48K	-42.98K	-130.03K	-124.3K	-89.98K	-538.09K
Capital Expenditures	0	-13.48K	-42.98K	-130.03K	-124.3K	-89.98K	-538.09K
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	4.51M	21.63M	101.2M	143.67M	8.65M	325.39M	2.68M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	-836.18K	-1.31M	-13.15M	-839.97K	-17.3M	592K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-3.92M	-6.69M	-21.54M	-44.73M	-67.29M	-93.14M	-120.67M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-0.71%	-2.22%	-1.08%	-0.5%	-0.38%	-0.3%
FCF per Share	-0.12	-0.21	-0.71	-1.47	-2.00	-2.43	-2.23
FCF Conversion (FCF/Net Income)	0.91x	0.74x	0.73x	1.04x	0.88x	0.92x	0.90x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-87.1%	-76.05%	-51.76%	-28.42%	-43.1%	-37.83%	-41.18%
Debt / Equity	-	-	-	0.00x	0.00x	0.00x	0.00x
Interest Coverage	-	-	-308.28x	-194.62x	-5384.33x	-	-
FCF Conversion	0.91x	0.74x	0.73x	1.04x	0.88x	0.92x	0.90x

Frequently Asked Questions

Growth & Financials

Pharvaris N.V. (PHVS) grew revenue by 0.0% over the past year. Growth has been modest.

Pharvaris N.V. (PHVS) reported a net loss of $166.0M for fiscal year 2024.

Dividend & Returns

Pharvaris N.V. (PHVS) has a return on equity (ROE) of -41.2%. Negative ROE indicates the company is unprofitable.

Pharvaris N.V. (PHVS) had negative free cash flow of $134.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener